{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T02:43:31Z","timestamp":1775097811068,"version":"3.50.1"},"reference-count":32,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,11,12]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>The cost of TKI for treatment of CML can be substantially saved by treatment discontinuation in patients who achieved DMR. Starting treatment with imatinib is the most cost-effective strategy even after incorporation of treatment discontinuation.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000745","type":"journal-article","created":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T15:42:35Z","timestamp":1572536555000},"page":"3266-3277","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":36,"title":["Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation"],"prefix":"10.1182","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5333-8414","authenticated-orcid":false,"given":"Chihiro","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotomo","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichiro","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiko","family":"Toda","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"Ito","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyomi","family":"Mashima","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nagayama","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kento","family":"Umino","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Minakata","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Nakano","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Morita","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoko","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyuki","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Ishihara","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Ashizawa","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Hatano","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Sato","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iekuni","family":"Oh","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichiro","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masuzu","family":"Ueda","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Ohmine","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Muroi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"},{"name":"Division of Cell Transplantation and Transfusion, Jichi Medical University, Shimotsuke, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2019,10,31]]},"reference":[{"issue":"23","key":"2019111520573525500_B1","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111520573525500_B2","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111520573525500_B3","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/ajh.24423","article-title":"Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034","volume":"91","author":"Shah","year":"2016","journal-title":"Am J Hematol"},{"issue":"1","key":"2019111520573525500_B4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2012.181","article-title":"Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"issue":"20","key":"2019111520573525500_B5","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111520573525500_B6","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"6","key":"2019111520573525500_B7","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2019111520573525500_B8","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw003","article-title":"Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States","volume":"108","author":"Padula","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"2019111520573525500_B9","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.jval.2011.07.006","article-title":"Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia","volume":"14","author":"Hoyle","year":"2011","journal-title":"Value Health"},{"issue":"7","key":"2019111520573525500_B10","first-page":"A639","article-title":"Decision analysis on the cost-effectiveness of sequential treatment strategies for patients with chronic myeloid leukemia in the United States","volume":"17","author":"Rochau","year":"2014","journal-title":"Value Health"},{"issue":"8","key":"2019111520573525500_B11","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.3109\/10428194.2014.982635","article-title":"Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia","volume":"56","author":"Rochau","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2019111520573525500_B12","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"3","key":"2019111520573525500_B13","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111520573525500_B14","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2019111520573525500_B15","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ajh.24120","article-title":"Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study","volume":"90","author":"Mori","year":"2015","journal-title":"Am J Hematol"},{"issue":"7","key":"2019111520573525500_B16","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/leu.2017.63","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study","volume":"31","author":"Hochhaus","year":"2017","journal-title":"Leukemia"},{"issue":"7","key":"2019111520573525500_B17","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study","volume":"129","author":"Rea","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2019111520573525500_B18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.clml.2018.03.004","article-title":"Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second-line treatment","volume":"18","author":"Okada","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2019111520573525500_B19","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"issue":"8","key":"2019111520573525500_B20","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1016\/S2352-3026(19)30087-0","article-title":"Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study","volume":"6","author":"Shih","year":"2019","journal-title":"Lancet Haematol"},{"issue":"2","key":"2019111520573525500_B21","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2009.011452","article-title":"Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib","volume":"95","author":"Shah","year":"2010","journal-title":"Haematologica"},{"issue":"15","key":"2019111520573525500_B22","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2013-10-532341","article-title":"Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study","volume":"123","author":"Shah","year":"2014","journal-title":"Blood"},{"issue":"35","key":"2019111520573525500_B23","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1200\/JCO.2011.40.5217","article-title":"Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib","volume":"30","author":"Branford","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111520573525500_B24","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.bbmt.2017.02.017","article-title":"Healthcare costs and utilization for patients age 50 to 64 years with acute myeloid leukemia treated with chemotherapy or with chemotherapy and allogeneic hematopoietic cell transplantation","volume":"23","author":"Preussler","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2019111520573525500_B25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.transproceed.2016.10.007","article-title":"Cost analysis of transplantation in Japan, performed with the use of the national database","volume":"49","author":"Kitazawa","year":"2017","journal-title":"Transplant Proc"},{"issue":"4","key":"2019111520573525500_B26","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hec.1481","article-title":"International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?","volume":"19","author":"Shiroiwa","year":"2010","journal-title":"Health Econ"},{"issue":"12","key":"2019111520573525500_B27","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","article-title":"Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial","volume":"2","author":"Imagawa","year":"2015","journal-title":"Lancet Haematol"},{"issue":"5","key":"2019111520573525500_B28","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00432-018-2604-x","article-title":"Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study","volume":"144","author":"Ross","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"issue":"22","key":"2019111520573525500_B29","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1002\/cncr.30885","article-title":"Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia","volume":"123","author":"Legros","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"2019111520573525500_B30","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1524-4733.2009.00573.x","article-title":"A multinational study of health state preference values associated with chronic myelogenous leukemia","volume":"13","author":"Szabo","year":"2010","journal-title":"Value Health"},{"issue":"12","key":"2019111520573525500_B31","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","article-title":"The effects of imatinib on pregnancy outcome","volume":"111","author":"Pye","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2019111520573525500_B32","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/21\/3266\/1505899\/advancesadv2019000745.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/21\/3266\/1505899\/advancesadv2019000745.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T23:40:20Z","timestamp":1573861220000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/21\/3266\/422670\/Analysis-of-the-costeffectiveness-of-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,31]]},"references-count":32,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2019,11,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000745","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,31]]}}}